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Abstract
Objectives. To assess non-invasive imaging for detection and quantification of gland structure, inflammation and
function in patients with primary Sjogren’s syndrome (pSS) using PET-CT with 11C-Methionine (11C-MET; radiola-
belled amino acid), and 18F-fluorodeoxyglucose (18F-FDG; glucose uptake marker), to assess protein synthesis and
inflammation, respectively; multiparametric MRI evaluated salivary gland structural and physiological changes.
Methods. In this imaging/clinical/histology comparative study (GSK study 203818; NCT02899377) patients with
pSS and age- and sex-matched healthy volunteers underwent MRI of the salivary glands and 11C-MET PET-CT.
Patients also underwent 18F-FDG PET-CT and labial salivary gland biopsies. Clinical and biomarker assessments
were performed. Primary endpoints were semi-quantitative parameters of 11C-MET and 18F-FDG uptake in subman-
dibular and parotid salivary glands and quantitative MRI measures of structure and inflammation. Clinical and minor
salivary gland histological parameter correlations were explored.
Results. Twelve patients with pSS and 13 healthy volunteers were included. Lower 11C-MET uptake in parotid,
submandibular and lacrimal glands, lower submandibular gland volume, higher MRI fat fraction, and lower pure dif-
fusion in parotid and submandibular glands were observed in patients vs healthy volunteer, consistent with reduced
synthetic function. Disease duration correlated positively with fat fraction and negatively with 11C-MET and 18F-FDG
uptake, consistent with impaired function, inflammation and fatty replacement over time. Lacrimal gland 11C-MET
uptake positively correlated with tear flow in patients, and parotid gland 18F-FDG uptake positively correlated with
salivary gland CD20þ B-cell infiltration.
Conclusion. Molecular imaging and MRI may be useful tools to non-invasively assess loss of glandular function,
increased glandular inflammation and fat accumulation in pSS.
Key words: SS, MRI, CT scanning, radionuclide imaging, diagnostic imaging, outcome measures and
histopathology
Introduction
Primary SS (pSS) is a systemic auto-inflammatory
rheumatic disease with unknown etiopathogenesis in
which the autoimmune reaction targets the salivary and
lacrimal glands. Dry mouth (xerostomia) and dry eyes
(keratoconjunctivitis sicca) are two of the main symp-
toms of pSS [1, 2], although multiple organs and mu-
cosal surfaces may be affected [3, 4]. There is
currently no disease-modifying drug for pSS, and the
disease has a significant detrimental impact on quality
of life [5].
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Early pSS diagnosis and assessment of disease activ-
ity are hampered by non-specific clinical manifestations,
subjective symptoms and a lack of specific or quantita-
tive biomarkers. Moreover, standard diagnostic and dis-
ease monitoring techniques [6, 7] have drawbacks,
including sampling errors from biopsies, and variability
in salivary and tear flow assays. Although salivary gland
ultrasound has been explored as a potential surrogate
for salivary gland biopsies [8], the absence of a vali-
dated scoring system and inherent inter-observer vari-
ability restrict its use as a reliable tool. Non-invasive
molecular imaging methods that can quantify function
could be attractive tools for assessing disease status
and potentially monitoring treatment effects.
This study assessed the potential of three functional
imaging methods for the quantification of salivary gland
structure, inflammation and function in patients with
pSS. First, positron emission tomography-computed
tomography (PET-CT) with 11C-methionine (11C-MET)
was used as a protein synthesis marker. As 11C-MET is
prominently incorporated into cellular proteins [9, 10], it
can assess residual salivary gland function. Second,
18F-fluorodeoxyglucose (18F-FDG) PET-CT, which indi-
cates metabolic tissue activity in tumours [11, 12] and
inflammation due to the higher expression of glucose
transporters and glycolytic index in inflammatory cells
[4, 13–16], was used to assess glucose utilization. The
ability to evaluate systemic manifestations of pSS using
18F-FDG was also examined [15]. Finally, multi-
parametric MRI was conducted to assess gland inflam-
mation, structure and function [17]. This is the first time
11C-MET has been used to characterize salivary gland
inflammation and residual function in pSS.
Methods
Study design
The study (GSK study 203818; NCT02899377) duration
was 14 weeks for patients with pSS, and 11 weeks
for healthy volunteers (HVs). Study design (Supplemen-
tary Fig. S1, available at Rheumatology online) details
are summarized in the Supplementary Methods, avail-
able at Rheumatology online.
Endpoints
The primary endpoints were semi-quantitative parame-
ters of 11C-MET and 18F-FDG uptake in submandibular
and parotid salivary glands [standardized uptake value
(SUV), tissue to reference ratio (T/R; an additional
measure that provides a semi-quantitative description of
tracer kinetics), total inflammatory volume and quantita-
tive parameters of inflammation and tissue microstruc-
ture derived from multi-parametric MRI in the salivary
glands [exchange rate (Ktrans), apparent diffusion coeffi-
cient (ADC), pure diffusion coefficient (D) and micro-
vascular volume fraction (f)] (see Image acquisition and
analysis and Supplementary Materials, available at Rheu
matology online).
Exploratory endpoints included 11C-MET and 18F-FDG
uptake in lacrimal glands and association with markers
of disease activity and lacrimal gland function, and fur-
ther quantitative parameters of inflammation, function
and structure derived from multi-parametric MRI of the
salivary glands [Initial Rate of Enhancement, maximum
enhancement, fat fraction (%), pseudo-diffusion (D*) and
gland volume]. All secondary and exploratory endpoints
are summarized in the Supplementary Materials, avail-
able at Rheumatology online.
Ethical considerations
The study was performed in accordance with the princi-
ples of the International Council for Harmonization of
Technical Requirements for Pharmaceuticals for Human
Use, Good Clinical Practice, applicable country-specific
requirements and the Declaration of Helsinki. The study
was approved by the East of England – Cambridge East
National Research Ethics Committee (REC No.; 16/EE/
0296) and by the Administration of Radioactive
Substances Advisory Committee (ARSAC), UK
(Research Certificate No.: RPC 630/3925/35065). Written
informed consent was obtained from all participants.
Patient and public involvement
The informed consent form and study feasibility were
reviewed by a group of patients before submission for
ethical review.
Study population
Eligible patients were 30 years, diagnosed with pSS
according to the American-European Consensus Group
criteria [18], with evidence of glandular reserve function
(baseline unstimulated salivary flow of >0.0 ml/min or
stimulated baseline salivary flow >0.05 mL/min). Patients
also had systemically active disease defined by a
EULAR Sjögren’s Syndrome disease activity index
(ESSDAI) score of 5 points.
Patients diagnosed with secondary SS or another sys-
temic autoimmune disease, or who had a history of
Rheumatology key messages
. We examined 11C-Methionine, 18F-FDG PET-CT and multi-parametric MRI for quantitative pSS salivary gland
imaging.
. Patients with pSS had structural/functional differences in salivary and lacrimal glands versus healthy volunteers.
. Molecular imaging parameters correlated with disease characteristics, providing initial validation for quantitative as-
sessment of pSS.
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malignancy 5 years before screening or unresolved
acute or chronic infection were excluded.
HV were mean-age- and sex-matched to patients
(40 years for 11C-MET PET-CT plus MRI and 30 years
for MRI without 11C-MET PET-CT).
Full inclusion and exclusion criteria are listed in the
Supplementary Materials, available at Rheumatology
online.
Image acquisition and analysis
At Visit 1, patients and HV underwent an MRI of the sal-
ivary glands and 11C-MET PET-CT (dynamic scan of the
salivary glands followed by head-to-hip static scan);
patients also underwent static 18F-FDG PET-CT (head-
to-hip). 11C-MET PET-CT scans were acquired 30 min
after a standardized light meal to stimulate salivary flow.
18F-FDG PET-CT scans were acquired after 6 h of fast-
ing and 60 min after 18F-FDG administration. SUVs
(SUVmax and SUVpeak) and volumes were automatical-
ly extracted for each region of interest following region
of interest contouring. The parotid, submandibular and
lacrimal glands were analysed using 11C-MET and 18F-
FDG scans, as were the spleen, liver, thyroid and pan-
creas. Aorta blood pool was used as the reference re-
gion for T/R calculations. Total inflammatory volume
was not calculated as there were no anatomically rele-
vant areas indicative of inflamed tissue and/or focal up-
take within the organs.
Multi-parametric MRI of the salivary glands included
a T1w high resolution structural image, Dixon imaging,
diffusion-weighted imaging, quantitative T1 mapping
and dynamic contrast enhanced (DCE)-MRI, which
took place following administration of a gadolinium-
based contrast agent. Anatomical region of interests
were defined on structural MRI for parotid and sub-
mandibular glands. Diffusion-weighted MRI imaging
data were used to fit a multi-parametric intravoxel in-
coherent motion model [19], as well as a conventional
diffusion model to estimate the apparent diffusion co-
efficient (ADC).
Full details of image acquisition and analysis are in
the Supplementary Materials, available at Rheumatology
online.
Clinical and histological evaluations
Clinical and biomarker assessments for patients and HV
were performed at screening/baseline and Visit 2.
Tear flow and salivary flow measurements
Lacrimal flow was measured using the Schirmer’s test
(unanaesthetized) and quantified as mean length wet per
min (mm/min) over the two visits for each eye. Mean
basal and stimulated (by paraffin chew) salivary flow
were measured following standard procedures. Full
details are given in the Supplementary Materials, avail-
able at Rheumatology online.
Salivary gland biopsy
Minor (labial) salivary gland biopsy was performed for
patients at Visit 2. Salivary gland histological assess-
ments included evaluation of focus score histological
index (the number of mononuclear cell infiltrates con-
taining 50 cells in a 4-mm2 glandular tissue) [20]
assessed on haematoxylin and eosin staining; and the
detection of the immune infiltrate markers by immuno-
fluorescence (CD20þ B cells, IgGþ, IgAþ, and IgMþ
plasma cells [PC]). Slides from two cutting levels
(100 lm distance apart) were imaged using a
NanoZoomer S60 digital slide scanner and NanoZoomer
digital pathology viewer software version 2.6.13
(Hamamatsu Photonics K.K., Hamamatsu, Shizuoka,
Japan). Immunofluorescence staining of CD3, CD20 and
immunoglobulins was quantified using Fiji software [21]
and the area fraction of each marker was expressed as
the ratio of the stained area over the total area of saliv-
ary gland tissue. Full details are given in the
Supplementary Materials, including Supplementary
Table S1, available at Rheumatology online.
Safety evaluations
Adverse events (AEs), pregnancies, vital signs and clin-
ical laboratory tests were monitored throughout the
study.
Statistical analysis
Information on sample size is in the Supplementary
Materials, available at Rheumatology online. An explora-
tory comparison of patients vs HV was performed for
each 11C-MET PET-CT and multi-parametric MRI
derived quantitative parameter (data permitting), to esti-
mate a difference (ratio where normality assumptions
are not adequate) with 95% CI. Where 95% CI for differ-
ence were clearly above or below zero, this was
described as higher/lower than the reference value.
Pearson correlation (R) coefficient analyses were per-
formed to assess the relationship between different
imaging parameters and between imaging and clinical/
histological parameters, as pre-specified in the reporting
analysis plan. Correlations were defined as strong
(R 0.8); moderate (R0.5); or low (R 0.2). The study
was not statistically powered to detect significant differ-
ence for any parameters.
Results
Participant disposition and baseline characteristics
Twenty-five participants were included; 12 patients
and 13 HV (Supplementary Fig. S2, available at
Rheumatology online). Twelve HV completed MRI, of
whom eight underwent 11C-MET PET-CT. One HV
was withdrawn due to intolerance of the MRI (see
Safety section). Patients and HV were well matched for
age, sex and body weight; demographics are listed in
Table 1.
Quantitative pSS imaging
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Imaging methods reveal structural and metabolic
differences between patients with pSS and HV
There was substantially lower 11C-MET SUVpeak uptake
in the parotid and submandibular glands of patients
compared with HV, while a similar trend towards lower
uptake was observed for the lacrimal glands, indicating
reduced protein synthesis (Fig. 1, Supplementary Fig.
S3A and B and Supplementary Video S1, available at
Rheumatology online). T/R data were consistent with
11C-MET SUVpeak findings (Supplementary Table S2,
available at Rheumatology online). Higher 11C-MET
SUVpeak uptake was seen in the thyroid and liver of
patients vs HV, with trends towards higher uptake also
seen in the spleen and lumbar vertebrae (Fig. 1C), sug-
gesting increased metabolic activity in these organs, al-
though this requires further confirmation.
18F-FDG SUVmax was numerically higher in the par-
otid glands of patients compared with historical HV,
indicating higher glycolytic activity in the salivary glands
of patients (Fig. 1A) [15, 22]. Historical data for subman-
dibular 18F-FDG uptake were not available. 18F-FDG
SUVpeak values for parotid and submandibular glands
are shown in Supplementary Fig. S3C and D, available
at Rheumatology online. Uptake of 18F-FDG outside of
salivary glands in patients with pSS was reviewed;
TABLE 1 Demographics, baseline characteristics and disease characteristics of healthy volunteers and patients with pSS
Demographics Healthy
volunteers
(n 5 13)
Healthy volunteers who
underwent 11C-MET
PET-CT scan (n 5 8)
Patients with
pSS (n 5 12)
Overall
(n 5 25)
Age, mean (S.D.), yearsa 48.1 (13.87) 51.5 (13.29) 49.0 (13.70) 48.5 (13.51)
Sex, n (%)
Female 13 (100) 8 (100) 12 (100) 25 (100)
BMI, mean (range), kg/m2 25.59 (20.7–34.1) 25.80 (20.7–34.1) 27.07 (20.0–39.4) 26.30 (20.0–39.4)
Height, mean (range), cm 167.5 (159–182) 168.4 (159–182) 162.8 (152–174) 165.2 (152–182)
Weight, mean (range), kg 72.33 (53.7–113.0) 73.99 (53.7–113.0) 71.53 (51.4–91.0) 71.95 (51.4–113.0)
Ethnicity, n (%)
Not Hispanic or Latino 13 (100) 8 (100) 12 (100) 25 (100)
Race, n (%)
Black or African-
American
2 (15) 1 (13) 0 2 (8)
Asian—Central/South
Asian Heritage
0 0 3 (25) 3 (12)
Asian—South-East Asian
Heritage
0 0 1 (8) 1 (4)
White—White/
Caucasian/European
Heritage
10 (77) 7 (88) 5 (42) 15 (60)
Unknown 1 (8) 0 3 (25) 4 (16)
Disease characteristics, mean (range)
Disease duration, years — — 5.8 (0.25–38.7) —
ESSDAI final scoreb — — 8.6 (6–16) —
ESSPRI final scorec — — 6.361 (4.33–8.33) —
Salivary flow rated, ml/min
Basal unstimulated 0.353 (0.20–0.62) — 0.193 (0.01–0.60) —
Stimulated 1.958 (0.91–3.41) — 0.728 (0.05–1.97) —
Differencee 1.605 (0.63–3.21) — 0.535 (0.04–1.37) —
Strip length per minutef, mm/min
Right eye 5.46 (0.80–23.60) — 1.72 (0–7.00) —
Left eye 4.89 (0.20–11.29) — 1.67 (0–7.00) —
Complement, g/l
Component 3 — — 1.103 (0.77–1.62)
Component 4 (n¼11) — — 0.245 (0.07–0.39)
IgG, g/l — — 17.657 (6.70–26.73)
aAge imputed for missing date of birth.
bESSDAI Final Score is the sum of 12 activity-level domain scores.
cESSPRI Final Score is an average of pain, fatigue and dryness scales scores.
dMean salivary flow rate calculated using screening and Visit 2 mean salivary flow.
eDifference is calculated by subtracting basal salivary flow rate from stimulated flow rate.
fStrip length wet per min (mm/min) calculated as length (mm) paper wet divided by time taken to wet (min).
11C-MET: 11C-Methionine; ESSDAI: EULAR Sjögren’sn Syndrome Disease Activity Index; ESSPRI: EULAR Sjögren’s
Syndrome Patient Reported Index; pSS: primary SS.
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FIG. 1 11C-MET and 18F-FDG uptake between patients with pSS and HVs
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(A) 11C-MET SUVpeak in parotid, submandibular and lacrimal glands (pSS and HV) and 18F-FDG SUVmax in parotid
glands (pSS)a; (B) dynamic imaging (summations of the final 10 minutes, approx. 30–40 minutes post injection) of
11C-MET uptake in parotid, submandibular and lacrimal glands for HVs (top) and patients with pSS (bottom). (C) Point
estimate (95% CI) of mean SUVpeak difference (pSS-HV) for 11C-METb. aAggregated includes left and right salivary
gland parameters. Difference is difference between means. bFor 11C-MET SUVmax data, see Supplementary Fig. S7,
available at Rheumatology online. cGrey horizontal line indicates historical max SUV (mean [solid line]; þ2SD [dotted
line]) Basu S, Houseni M, Alavi A. Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its
impact on patient management. Nucl Med Commun 2008;29:367–73. 11C-MET: 11C-Methionine; 18F-FDG: 18F-fluoro-
deoxyglucose; HV: healthy volunteer; Max: maximum; pSS: primary SS; SUV: standardized uptake value.
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however, no clinically important findings were reported
following radiologist review. 18F-FDG uptake in different
regions of interest is shown in Supplementary Table S3,
available at Rheumatology online.
A substantially lower submandibular gland, but not
parotid gland, volume compared with HVs (Fig. 2) was
observed on MR volumetric assessment. Furthermore,
median (IQR) MRI fat fraction was higher in both the
parotid and submandibular glands of patients [36.4
(26.6, 52.1) and 21.8 (12.7, 35.1), respectively] relative to
HV [28.8 (20.4, 32.4) and 10.6 (9.9, 12.5), respectively],
possibly reflecting some fat replacement of functional
gland tissue in patients with pSS (Fig. 2). Patients also
demonstrated greater variability around the point esti-
mate of the fat fraction, compared with HV.
Substantially lower pure diffusion was also observed in
the parotid [mean (S.D.): 0.676 (0.1515)] and subman-
dibular glands [0.807 (0.3001)] of patients compared
with HV [0.787 (0.0950) and 0.993 (0.1415), respectively]
(Fig. 2), possibly reflecting higher cell density. Additional
MRI parameters are presented in Supplementary Fig.
S4, available at Rheumatology online.
Findings in the parotid glands of patients and HV from
either PET-CT or MRI were symmetrical when compar-
ing left/right (Supplementary Fig. S5, available at
Rheumatology online).
In HV, 11C-MET SUVpeak uptake was similar between
parotid and submandibular glands. However, in patients,
11C-MET SUVpeak uptake was lower in submandibular
compared with parotid glands, suggesting that protein
synthesis in the submandibular glands was
disproportionately affected in this group of pSS patients.
However, 18F-FDG SUVpeak uptake was similar in the
submandibular and parotid glands of patients.
Correlations between imaging methods
11C-MET and 18F-FDG SUVpeak uptake were positively
correlated in the parotid and submandibular glands of
patients (Fig. 3). 11C-MET and 18F-FDG SUVpeak dis-
played inverse strong and moderate correlations, re-
spectively, with fat fraction in both submandibular and
parotid glands of patients; again, this correlation was
strongest in the submandibular glands (Fig. 3). 11C-MET
displayed weakly negative correlations with fat fraction
in the parotid and submandibular glands of HV (Fig. 3).
Correlations between imaging data and disease
characteristics and histological measures
Imaging vs disease characteristics
In keeping with loss of salivary gland function over time
in patients with pSS, 11C-MET uptake was strongly
negatively correlated with disease duration. Similarly,
there was moderate negative correlation of 18F-FDG up-
take with time (Fig. 4A). In agreement with the PET find-
ings, MRI fat fraction was moderately positively
correlated with disease duration (Fig. 4A), while a strong
negative correlation was observed for MRI pure diffusion
median vs disease duration [0.808 (0.948, 0.403)].
Salivary flow was uniformly low in patients, and 11C-
MET and 18F-FDG SUVpeak demonstrated only a weak
positive correlation, or no correlation, with mean
FIG. 2 Differences in multi-parametric MRI measures between patients with pSS and HV
Point estimate (95% CI) of the geometric mean ratio (pSS/HV)a gland volume (cm3), fat fraction mean (%) and pure
diffusion median (103mm2/s) in the parotid and submandibular glands from the multi-parametric MRI scan. Ratios
are derived from the back-transformed estimate of the difference (pSS  HV) between log transformed means, and
95% CI are derived from the back-transformed estimate of the log 95% CI. CI is calculated using the Satterthwaite
approximation. HV: healthy volunteer; pSS: primary SS.
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stimulated salivary flow rate in the parotid glands of
patients (Fig. 4B). In contrast, lacrimal gland 11C-MET
SUVpeak positively correlated (strongly and moderately)
with tear flow rates in patients; however, none or weak
correlations were observed for HV (Fig. 4C).
Further correlation data can be found in
Supplementary Table S4, available at Rheumatology
online.
Imaging vs histological measures
Surprisingly, histological focus scores from minor sal-
ivary gland biopsy demonstrated no clear correlation
with either 11C-MET or 18F-FDG SUVpeak in patients
(Fig. 5A). A moderate positive correlation was
observed between 18F-FDG SUVpeak in the parotid
gland and CD20þ B-cell infiltration (or area fraction) in
the minor salivary gland of patients, suggesting that
increased FDG activity is reflective of a B-cell tissue
infiltrate. However, there was no such correlation be-
tween 11C-MET SUVpeak and CD20 (Fig. 5B), sug-
gesting that methionine activity is not confounded by
inflammation.
In the parotid gland of patients, moderate positive
correlations were noted between IgG deposition in
minor salivary gland biopsies, and both 11C-MET and
18F-FDG SUVpeak (Fig. 5C). Additionally, a moderate
positive correlation was shown between minor salivary
gland IgM and parotid gland 11C-MET SUVpeak [R
(95% CI): 0.505 (0.097, 0.836)] and a moderate nega-
tive correlation was shown between minor salivary
gland IgM and fat fraction [R (95% CI): 0.503 (0.860,
0.185)] in the parotid gland. Minor salivary gland IgA
was also moderately positively correlated with 11C-MET
SUVpeak [R (95% CI): 0.628 (0.085, 0.884)] in the par-
otid gland.
FIG. 3 Correlations between 11C-MET, 18F-FDG and MRI fat fraction imaging parameters
11C-MET: 11C-methionine; 18F-FDG: 18F-fluorodeoxyglucose; HV: healthy volunteer; pSS, primary SS; R, Pearson’s
correlation; SUV: standardized uptake value
Quantitative pSS imaging
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FIG. 4 Correlations between 11C-MET and 18F-FDG uptake and MRI fat fraction with disease characteristics
11C-MET and 18F-FDG peak SUV and MRI fat fraction correlations with (A) disease duration (years) and (B) stimulated
salivary flow rate and (C) correlation of tear flow with 11C-MET PET-CT peak SUV in the lacrimal gland. Data were
available for 10 patients only. 11C-MET: 11C-methionine; 18F-FDG: 18F-fluorodeoxyglucose; HV: healthy volunteer;
pSS: primary SS; R, Pearson’s correlation; SUV: standardized uptake value.
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FIG. 5 Correlations between 11C-MET and 18F-FDG uptake with histological markers
(A) 11C-MET and 18F-FDG SUVpeak in parotid gland correlations with focus score; representative histological image
of minor salivary gland lobule stained for haematoloxylin and eosin (H&E) for focus score assessment. Highlighted
section identifies an inflammatory focus, defined as an aggregate of at least 50 inflammatory mononuclear cells. (B)
11C-MET and 18F-FDG SUVpeak in parotid gland correlated with CD20; representative immunofluorescence staining
for CD20 identifying B cells within inflammatory aggregates in pSS. (C) 11C-MET and 18F-FDG SUVpeak in parotid
gland correlated with IgG in minor salivary gland; representative immunofluorescence staining for IgA, IgG and IgM,
expressed by plasma cells in pSS. 11C-MET: 11C-methionine; 18F-FDG: 18F-fluorodeoxyglucose; HV: healthy volun-
teer; pSS, primary SS; R, Pearson’s correlation; SUV: standardized uptake value.
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Safety
Overall, study procedures were well tolerated. Four
patients and two HV reported AEs most commonly
headache, reported in one patient and one HV
(Supplementary Table S5, available at Rheumatology on-
line). Most AEs were mild in intensity. One HV was with-
drawn from the study because of hyperaesthesia and
paraesthesia experienced during the MRI scan; these
AEs were moderate in intensity and deemed unrelated
to the study procedures. No deaths or serious AEs were
reported.
Discussion
This is the first evaluation of the amino acid PET tracer
11C-MET in patients with pSS. Additionally, the applica-
tion of MRI and 18F-FDG PET-CT to quantify and char-
acterize disease manifestations in pSS were evaluated
in this imaging/histology comparative study.
Lower 11C-MET uptake was observed in the subman-
dibular and parotid glands of patients compared with
HV, in addition to a trend towards lower uptake in the
lacrimal glands, suggesting lower protein synthesis in
patients than in HV. Although 11C-MET data alone do
not distinguish whether such protein synthesis would be
attributable to synthesis of saliva or inflammation, the
lower uptake would be consistent with loss of glandular
function [9, 10]. Together with the strong negative cor-
relation between disease duration and 11C-MET uptake
in the parotid gland, and the correlations between 11C-
MET uptake and lacrimal tear flow, our findings suggest
that reduced 11C-MET uptake is a marker of residual
gland function. Notable confounding factors may be the
tendency for older participants to have longer disease
duration and the known minor decline in salivary gland
function with age, even in healthy individuals [23], al-
though patients were age-matched to HV.
Surprisingly, 11C-MET uptake did not correlate with
salivary flow rates, possibly due to the impact of factors
other than gland function on salivary flow (e.g. diurnal
variation in flow rates, patients’ hydration status at time
of collection, pH and viscosity of saliva, dental plaque
status, tongue pressure and coating status). One possi-
bility is that gland inflammation itself can reduce salivary
gland function, independent of loss of protein synthetic
activity. However, salivary flow rate data for patients
with pSS were skewed towards low values, thus affect-
ing quantitation accuracy as the correlation estimations
assume normal distribution; therefore, these results
should be interpreted with caution.
Parotid gland 18F-FDG uptake tended to be higher in
patients with pSS compared with previously published
control data [22, 24]; and there was a moderate negative
correlation with disease duration, whilst a positive cor-
relation was observed with 11C-MET uptake. It is worth
noting that patients with pSS were at different disease
stages and overall displayed high 18F-FDG uptake and
lower 11C-MET uptake compared with HV, consistent
with greater salivary gland inflammation and loss of
functional reserve. The positive correlation between 18F-
FDG and 11C-MET in patients with pSS can be
explained by considering overall disease course, in
which it is expected that both 18F-FDG and 11C-MET
uptake declines from high to normal (18F-FDG) and nor-
mal to low (11C-MET) as the disease progresses, re-
spectively (Supplementary Fig. S6, available at
Rheumatology online), as is supported by the study data
(Fig. 4A). Overall, we hypothesize that inflammation
occurs early in the disease course and is associated
with relatively preserved underlying gland function,
which transitions to a decline in both inflammation and
gland function from early to late disease, thereby
explaining the positive correlation between the 18F-FDG
and 11C-MET imaging parameters. Alternatively, both
tracers could be primarily affected by cellular integrity,
rather than 18F-FDG being a measure of inflammation,
and 11C-MET of function. Notably, leucocyte infiltration
has not been reported to increase 11C-MET uptake to
the same degree as 18F-FDG [25]. However, there were
stronger correlations of 18F-FDG with markers of inflam-
mation (CD20þ B-cell infiltration) and 11C-MET with
accepted markers of function (tear flow), suggesting that
they measure different aspects of disease. Parotid gland
18F-FDG uptake did not correlate with histological focus
score on minor salivary gland biopsy. It is unclear why
such a correlation could not be observed, as it has been
demonstrated that minor salivary gland focus score cor-
relates with inflammation in parotid glands in an ultra-
sound study [26]. Furthermore, moderate correlations
were seen with CD20 infiltration and IgG deposition in
minor salivary gland, supporting the hypothesis that 18F-
FDG uptake may be a measure of inflammation; how-
ever, this may be due to sample size.
Outside of the salivary glands, 11C-MET uptake was
higher in the thyroid and liver of patients with pSS com-
pared with HV, suggesting increased protein synthesis.
Although no patients with pSS were reported to be clin-
ically affected by thyroiditis, an association between thy-
roid disease, most frequently subclinical hypothyroidism,
and pSS has been reported [27]; however, this was not
supported by the physiological levels of 18F-FDG uptake
in the thyroids of corresponding patients in our study.
Overall, the small sample size prevents further conclu-
sions being drawn.
Variable 18F-FDG uptake was observed across mul-
tiple organs, but no findings were considered clinically
abnormal. In contrast, a study by Cohen et al. [15]
observed abnormal uptake in organs including lung,
lymph nodes and thyroid. However, the patient subsets
recruited included those with lung involvement and sus-
pected lymphoma, whereas clinical suspicion of lymph-
oma was an exclusion criterion for this study.
Furthermore, methods of analysis and definitions of
positive uptake differed between the studies.
The Dixon method, used to estimate fat fraction from
structural MRI, has previously been used to successfully
Pilar Jimenez-Royo et al.
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measure the characteristic fat deposition in the parotid
glands of patients with pSS [28]. Diffusion-weighted
imaging and entropy of parotid glands previously
enabled discrimination between patients with active and
non-active pSS [29]. In this study, evidence from MRI,
including higher fat fraction and lower pure diffusion in
the glands of patients compared with HV and correlation
of both fat fraction and pure diffusion (positive and
negative, respectively) with disease duration, is suggest-
ive of fatty replacement of functional gland tissue, which
has been shown to occur as glandular atrophy and dis-
ease progression occurs. Fat fraction was also negative-
ly correlated with 11C-MET and 18F-FDG uptake.
Together, these data support the use of MRI, particularly
fat fraction and pure diffusion parameters, in the non-
invasive characterization of pSS. These findings are con-
sistent with a small study that demonstrated a correl-
ation between MRI findings and disease stage in
patients with secondary SS [30].
Overall, these results corroborate a hypothesis in
which pSS may start with inflammatory reactions that
are followed by deterioration of salivary and lacrimal
gland function and a gradual atrophy that includes re-
placement of glandular cells with fat [31]. The observa-
tion of retained right–left symmetry, which is consistent
with previous work [10], indicates that the disease is
global and not sporadically attacking one specific gland.
Intra-individual differences seen in imaging parameters
of parotid and submandibular glands indicate that the
disease manifestation may separately affect the parotid
or submandibular glands to different degrees.
Study limitations include the use of historical control
data for the 18F-FDG analyses, which did not allow pre-
cise comparisons between patients and controls, and
analysis of correlations between imaging vs function/
clinical parameters in the parotid gland only (for tech-
nical reasons for DCE-MRI and to limit the number of
comparisons conducted). However, with a few excep-
tions, the major findings between the parotid and sub-
mandibular glands were similar. Parotid imaging
parameters only were correlated with overall salivary
flow, although the disease generally does involve both
parotid and submandibular glands. Finally, the imaging
techniques used were not compared with ultrasound
examination of the salivary glands.
In conclusion, 11C-MET scans of the salivary and lac-
rimal glands in patients with pSS have the potential to
quantitatively assess residual function in individual
glands, while 18F-FDG is a potential method to assess
salivary gland inflammation. These imaging modalities
may facilitate non-invasive assessment of patients with
pSS, particularly in early phase clinical trials. 11C-MET
PET-CT, 18F-FDG PET-CT and MRI fat fraction could be
used to define patients with inflammation (as measured
by increased 18F-FDG uptake) along with relatively
preserved residual salivary gland function (preserved
11C-MET uptake) as opposed to patients with severe
dysfunction; the former ‘sub-group’ potentially being
better candidates for drug therapy. Additionally,
although not evaluated here, some of these parameters
could be used in future interventional studies to assess
the mechanistic effects of therapeutic interventions,
complementing clinical scoring.
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